MedTrace Logo

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-07-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see whether ASP-1001 when given as a nasal spray is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever) following nasal challenge with antigen.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

ASP-1001 nasal spray

2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.

DRUG

Placebo for ASP-1001

2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.

Sponsors & Collaborators

  • Asphelia Pharmaceuticals

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Robert Naclerio, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Days
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791102 on ClinicalTrials.gov